Aragon Surgical: Start-Up Diversifies Early
This article was originally published in Start Up
One of the golden rules of medical device start-ups is maintaining focus. That's why it was somewhat surprising to see that Aragon Surgical Inc., a start-up just emerging from stealth status, launched by veteran device investors Leslie Bottorff of Onset Ventures and David Douglass and John Maroney of Delphi Ventures, had recently completed an acquisition of a second product while its primary product still remains very much in the development stage.
You may also be interested in...
Start-Up analyzes fundraising and alliances among start-ups in the biopharmaceutical, medical device and in vitro diagnostics segments from January through March 2008. Data comes from Windhover’s Strategic Transactions Database.
Novasys Medical is using radio frequency (RF) energy to treat stress urinary incontinence in women. The company chose to adopt a much more rigorous and expensive clinical trials strategy than was needed to gain FDA approval of its device. This approach flummoxed the FDA,, slowing approval of the company's IRenessaI system. Novasys is betting that the enhanced data collected from its clinical study will result in the company gaining faster reimbursement that it hopes will drive adoption.
Amunix’s XTEN technology for half-life extension and precise drug delivery has been used by multiple partners over the past 15 years, but now the firm is building its own cancer therapy pipeline.